SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending due to high volume and price volatility, sparking discussions around potential insider selling following a lock-up period expiration. The community is debating whether the dip represents a buying opportunity or a sign of further declines, with some citing oversold conditions and potential for a rebound. Others express concern over the company's fundamentals and the impact of potential dilution.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Recursion Pharmaceuticals Inc

RXRX is trending as traders discuss the potential for a short squeeze, pointing to its high short interest and unusual options activity. Some believe the company's AI-driven drug discovery platform and partnerships with companies like NVDA could be a catalyst. Others remain cautious, noting concerns around cash burn and insider selling.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently closed $75 million investment focused on AI connectivity, fueling speculation about the institutional investor behind the deal and potential strategic implications for the company. Community discussions revolve around POET's role in addressing bottlenecks in AI data centers and the potential for partnerships or M&A activity in the AI hardware space. Bullish sentiment is high, with many anticipating significant upside potential and comparing it to other high-growth tech sectors.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings ($AREB) is trending amidst discussions around trading halts, potential breakout points, and the stock's history of multi-day runs. Community members are actively debating its short-squeeze potential and consolidation patterns, with some pointing to a possible 'squirt' to higher levels. Additionally, the buzz around recent biotech releases is contributing to the heightened interest in $AREB.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending amid renewed buyout speculation and anticipation for upcoming trial catalysts, especially following competitor acquisitions in the obesity and NASH space. Community members highlight VKTX's strong pipeline, potential for best-in-class efficacy, and a growing sense that the market is undervaluing the stock relative to recent deals. A possible short squeeze due to high short interest also fuels interest.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as investors flock to the safe-haven asset amid concerns about the government shutdown and broader economic uncertainty. Community chatter highlights gold's potential to reach new highs, with some viewing it as a hedge against potential market downturns or a declining dollar. Discussions also include the relationship between gold, equities, and crypto.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending as investors discuss its potential for a short squeeze given the high short interest and recent insider buying, while others are anticipating news from upcoming conferences. Bullish sentiment is fueled by the long-term potential of gene editing and CRISPR's diverse pipeline, including its commercial success with Casgevy. Some traders are eyeing resistance levels, speculating on trial breakthroughs, and monitoring for analyst upgrades as potential catalysts.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential for a short squeeze, citing a small float and high short interest. The community is also focused on upcoming data releases and potential partnerships, viewing the stock as undervalued within the cancer immunotherapy sector. Some are expressing frustration with the stock's performance despite positive clinical data.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending after announcing a commercial agreement with Verizon to bring satellite-based cellular broadband to the US by 2026, driving excitement about the company's potential. Community members are actively discussing the partnership's implications, potential revenue, and the possibility of a short squeeze, while some are wary of the high valuation. The stock's surge reflects broader interest in the space-based communications sector.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital (ATON) is trending due to its focus on tokenizing its mesothelioma treatment program and merging blockchain technology with cancer therapeutics, sparking debate about the company's direction. Community discussions revolve around potential pump-and-dump schemes and the stock's volatility, while some see opportunity in its unique approach to decentralized science. ATON's movements are also being compared to other volatile stocks like XBIO, NXL and ECDA, with traders actively seeking the next high-potential runner.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

U.K.-based biopharmaceutical company GSK plc (GSK) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/">said</a> on Friday that the European Medicines Agency (EMA) has accepted its regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 years or above.Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease due to underlying medical conditions.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, GSK said. The virus can aggravate conditions such as asthma and chronic heart failure, leading to hospitalisation and death.The company is looking forward to a decision from the regulator on the application in the first half of 2026.Meanwhile, the firm is continuing to seek an expansion for the treatment scope of its RSV vaccine in geographies including the U.S. and Japan.Arexvy brought in 78 million British pounds ($106.08 million) for GSK in the first quarter of 2025, down 57% from the corresponding period of 2024, following a drop in sales in the U.S., and accounting for just 1% of its overall turnover in the period.On Stocktwits, retail sentiment around GSK remained unmoved within ‘extremely bearish’ territory over the past 24 hours while message volume remained unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1258/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_12_12_04_PM_png_f36e4b25b0.webp" alt="GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1258" height="126"><figcaption>GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are down by 3% as of Friday noon. <a href="https://stocktwits.com/symbol/GSK">The stock</a> is up approximately 22% this year and has increased by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism

The company is looking forward to a decision from the regulator on the application in the first half of 2026.

Equity

Toyota Industries is expected to announce that it will accept a takeover bid from Toyota Motor Corp. (TM) and other group companies as early as Tuesday, Nikkei Asia <a target="_blank" rel="noopener noreferrer nofollow" href="https://asia.nikkei.com/Business/Business-deals/Toyota-Industries-to-announce-acceptance-of-42bn-takeover-bid">reported</a> on Monday.The consortium is expected to take Toyota Industries private after the firm accepts the tender offer, the report added. The takeover bid is estimated to be 6 trillion yen, or approximately $42 billion.Toyota Industries develops and manufactures automobiles and automobile-related products, such as vehicles, engines, car air-conditioning compressors, car electronics components and devices, and stamping dies. It also develops and produces the RAV4 for Toyota Motor.The companies maintained a close relationship after Toyota Motor was spun off from Toyota Industries in 1937.In FY2024, net sales to Toyota Motor accounted for 12.8% of Toyota Industries’ consolidated net sales. As of March 31, 2024, TMC also held 24.7% of Toyota Industries’ voting rights.The carmaker had said in April that it is exploring investing in the potential buyout of its supplier.Toyota is the largest automaker in the world in terms of global sales. In 2024 alone, the company sold 10.8 million vehicles.Last month, the company also said that its worldwide sales and production rose for the fourth consecutive month in April.The company’s global sales jumped 10% to 876,864 units in April on the back of a near 12% jump in sales within Japan and a near 10% increase in sales outside the home country.On Stocktwits, retail investor sentiment about Toyota remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:636/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_1_30_22_PM_png_979a999514.webp" alt="TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits" width="636" height="67"><figcaption>TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> NYSE-listed shares of <a href="https://stocktwits.com/symbol/TM/sentiment">Toyota</a> traded over 1% lower on Monday. The stock is down by about 3% this year and by over 11% over the past 12 months.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/muln-automotive-raises-stake-in-bollinger-motors/chkYEF6RbHg">Mullen Automotive Raises Stake In Bollinger Motors To 95%, Trading Activity Halts As Stock Undergoes Reverse Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided

The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion.

Toyota Motor Corp. (TM) <a target="_blank" rel="noopener noreferrer nofollow" href="https://global.toyota/en/company/profile/production-sales-figures/202504.html">said</a> on Thursday that its worldwide sales and production rose for the fourth consecutive month in April, sending the NYSE-listed shares of the Japanese automaker over 2% higher in pre-market.The company’s global sales jumped 10% to 876,864 units on the back of a near 12% jump in sales within Japan and a near 10% increase in sales outside the home country. This includes sales of its Toyota and Lexus brand vehicles.While sales rose 10% in the U.S. owing to a rush in demand before Trump tariffs took effect, sales in China rose 21% on the back of sales promotion measures undertaken by dealerships. However, the market in China remains challenging, with a shift to new energy vehicles and intensifying price competition, Toyota noted.In Japan, the launch of new vehicle models aided the sales growth.Vehicle production, meanwhile, rose 8% in April after manufacturing within Japan rose 7% and production outside the home country rose over 8%. While production in Japan was aided by the launch of new vehicles, production outside the country was supported by strong demand, the company said.Toyota had a significant 25% jump in sales of electrified vehicles last month, owing to a 24% increase in sales of hybrid electric vehicles in particular, which touched 378,976 units, accounting for about 43% of the company’s overall sales in the month.On Stocktwits, retail investor sentiment about Toyota improved from ‘extremely bearish’ to ‘bearish’ territory while message volume rose from ‘low’ to ‘normal’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_7_16_02_AM_png_1ea08e8c9f.webp" alt="TM's Sentiment Meter and Message Volume as of 7:15 a.m. ET on May 29, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>TM's Sentiment Meter and Message Volume as of 7:15 a.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/TM">TM stock</a> is down approximately 5% this year and nearly 15% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/c3-ai-stock-poised-for-best-day-in-6-months-on-q4-beat-positive-guidance/ch0AmZDRbtS">C3.ai Stock Poised For Best Day In 6 Months On Q4 Beat, Positive Guidance: Retail’s Exuberant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Toyota Records Fourth Straight Month Of Sales Jump In April: But Retail’s Not Yet Convinced

The company reported a 25% jump in sales of electrified vehicles last month, owing to a 24% increase in sales of hybrid electric vehicles in particular, which touched 378,976 units.

French pharmaceutical major Sanofi SA (SNY) on Tuesday reportedly launched a vaccine manufacturing facility in Vietnam with Vietnam Vaccine JSC (VNVC). Following the news, Nasdaq-listed shares of Sanofi traded 2% higher in Tuesday’s premarket.The new facility is designed to produce vaccines for use in Vietnam as well as for export, according to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-vnvc-launch-vaccine-factory-vietnam-2025-05-27/">report</a>. It added that French President Emmanuel Macron, who is currently visiting Vietnam, witnessed the launch.The plant spans 2.6 hectares and is situated in Long An. It has received an initial investment of two trillion dong ($77.15 million), the report said, citing a statement from VNVC.The new facility is slated to produce 100 million vaccine doses annually, although it is unclear which vaccines will be produced.Operations are expected to begin by 2027-end, the report added.Sanofi, renowned for its vaccines, reported an 11.4% surge in vaccine sales in the first quarter to €1.3 billion ($1.48 billion). The company’s total sales in the quarter came in at €9.9 billion, marking an increase of 9.7% at constant exchange rate.Sanofi makes vaccines against RSV lung infection, Polio, Influenza, whooping cough, and Meningitis, among others. The company is also developing and studying a vaccine against Chlamydia.The company stated that over 500 million people are vaccinated annually with its vaccines worldwide, and it supplies 2.5 million vaccine doses every day.On Stocktwits, retail sentiment around SNY stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_7_21_45_AM_png_e41808b018.webp" alt="SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits" width="628" height="63"><figcaption>SNY's Sentiment Meter and Message Volume as of 7:20 a.m. ET on May 27, 2025 | Source: Stocktwits</figcaption></figure> According to Koyfin data, 16 of 21 analysts covering Sanofi rate it ‘Buy’ or higher, while five rate it a ‘Hold’.<a href="https://stocktwits.com/symbol/SNY">SNY stock</a> is up by about 8% this year and by over 8% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/info-edge-tests-key-support-sebi-ra-financial-sarthis-says-breakout-above-1-510-could-signal-upside/ch0VIWGRbAz">Info Edge Tests Key Support: SEBI RA Financial Sarthis Says Breakout Above ₹1,510 Could Signal Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: 1 Vietnamese Dong = 0.000039 USD &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 1 Euro = 1.14 USD

Photo taken on April 15, 2025 shows the pharmaceutical factory of pharmaceutical company Sanofi in Hangzhou, Zhejiang province, China. (Photo credit should read CFOTO/Future Publishing via Getty Images)

Sanofi, VNVC Launch Vaccine Manufacturing Facility In Vietnam, Says Report: Retail’s Positive

According to Reuters, operations at the new facility are expected to begin by the end of 2027. 

Japanese automaker Toyota Motor (TM) expects operating income for fiscal year 2026 to fall 21% year-on-year to 3,800 billion yen ($26.25 billion), owing to factors including U.S. tariffs on vehicle imports.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://global.toyota/pages/global_toyota/ir/financial-results/2025_4q_summary_en.pdf">said</a> that the new forecast includes a negative impact of 180 billion yen from U.S. tariffs for April and May, and an estimated 745 billion yen from the effects of the foreign exchange rate.The carmaker expects revenue to rise 1% to 48.5 trillion yen in FY26 due to higher retail vehicle sales. However, the impact of U.S. tariffs and other factors has made it difficult to anticipate the business outlook, the company said.For the fiscal year ending March 2025, the company reported total sales revenue of 48,036.70 billion yen, marking a growth of 6.5% YoY, and above an analyst estimate of 47.67 trillion yen, per Finchat data.Operating income, however, fell 10.4% to 4,795.59 billion yen during the fiscal year, particularly owing to a 78.5% drop in operating income to 108.8 billion yen in North America during the period.Operating income in Japan, the company's home country, also fell 9.6% in the fiscal year to 3,151.1 billion yen.Earnings per share for the year subsequently fell to 359.56 yen from 365.94 yen in FY24, above an estimated 338.46 yen. &nbsp;On Stocktwits, retail sentiment around Toyota stayed unmoved within the ‘bullish’ territory over the past 24% hours while message volume remained at ‘low’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:631/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_08_at_8_15_44_AM_png_296971f794.webp" alt="TM's Sentiment Meter and Message Volume as of 8:10 a.m. ET on May 8, 2025 | Source: Stocktwits" width="631" height="61"><figcaption>TM's Sentiment Meter and Message Volume as of 8:10 a.m. ET on May 8, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/TM/sentiment">TM stock</a> is trading 2% lower in pre-market on Thursday.The stock has been down by over 2% year-to-date and by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-india-head-resigns/chifSsERbkB">Tesla India Head Resigns Ahead Of Planned Launch In Country, Says Report: Retail Continues To Be Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 Japanese Yen = 0.0069 USD)

Toyota Expects 21% Profit Decline In FY26: Retail’s In Wait-And-Watch Mode

The company said that the new forecast includes a negative impact of 180 billion yen from U.S. tariffs for April and May, and an estimated 745 billion yen impact from the effects of the foreign exchange rate.

Japanese automaker Honda Motor Co (HMC) is considering moving the production of its hybrid Civic model to the U.S. from Japan in light of Trump’s tariffs, according to a Bloomberg report.A company spokesperson <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-04-16/honda-to-shift-production-of-civic-from-japan-to-us-on-tariffs?sref&amp;">told</a> Bloomberg that production of the five-door hybrid model, which began in February in Saitama prefecture in central Japan, will be relocated to Honda’s plant in Indiana around June or July.The spokesperson said the decision was based on external factors, including the Trump administration’s imposition of tariffs on cars manufactured outside the country and imported into the U.S. Tariffs on auto parts are expected to take effect no later than May 3.Trump said on Monday that he is looking to “help some of the car companies” as automakers “need a little bit of time” to move their production to the U.S., raising hopes among investors for some reprieve in the tariffs.In 2024, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://global.honda/en/newsroom/news/2025/c250130aeng.html">produced</a> 3.73 million vehicles globally, of which 693,259 were made in Japan and over a million units in the U.S. Notably, 5,379 vehicles were exported from Japan to the U.S. during the calendar year.Following reports that Honda is considering moving production from Mexico and Canada to the U.S., Mexico Economy Minister Marcelo Ebrard highlighted earlier this week that the company’s executives have told the Mexican government there are no changes in its production plan in the country. &nbsp;On Stocktwits, retail sentiment around Honda fell 14 points further into the ‘extremely bearish’ territory while message volume jumped from ‘high’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:647/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_8_20_40_AM_png_4ff9eabc21.webp" alt="HMC's Sentiment Meter and Message Volume as of 8:20 a.m. ET on April 16, 2025 | Source: Stocktwits" width="647" height="149"><figcaption>HMC's Sentiment Meter and Message Volume as of 8:20 a.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/HMC">HMC stock </a>is up by about 0.5% year-to-date but down by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-245-china-tariffs-push-gold-beyond-the-3300-mark-newmont-barrick-stocks-gain/chQPjUFRbOm">Trump’s 245% China Tariffs Push Gold Beyond The $3,300 Mark – Newmont, Barrick Stocks Gain Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Honda sign on building exterior along North Main Street, Walnut Creek, California, March 6, 2025. (Photo by Smith Collection/Gado/Getty Images)

Honda Eyes Shifting Production Of Hybrid Civic From Japan To US, Says Report: Retail’s Skeptical

A Honda spokesperson told Bloomberg that the decision was based on external factors, including the Trump administration’s tariffs.

First Trust Exchange-Traded Fund III - First Trust Value Line Dividend Index Fund

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$46.16
Prev Close	$46.14
Open	$46.23
Dividend Yield	N/A
50-Day Moving Average	$45.94
Beta	N/A
Avg. Volume	521,833.14
PE Ratio	N/A

52-Week High	$47.01
52-Week Low	$40.06
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

FVD
First Trust Exchange-Traded Fund III - First Trust Value Line Dividend Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FVD News

FVD First Trust Exchange-Traded Fund III - First Trust Value Line Dividend Index Fund